Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
TINDAMAX (tinidazole) is an oral antiprotozoal and antibacterial agent approved in 2004 for treating parasitic and bacterial infections. It is a nitroimidazole derivative that works by disrupting DNA synthesis in susceptible organisms. The drug is indicated for infections caused by protozoa and anaerobic bacteria, serving as an alternative to metronidazole in select patient populations.
Product is approaching loss of exclusivity with moderate competitive pressure (30), suggesting reduced team investment and potential organizational transitions for brand personnel.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
Treatment of Bacterial Vaginosis With Oral Tinidazole
Treatment of Bacterial Vaginosis (BV) With Tinidazole
Worked on TINDAMAX at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TINDAMAX offers limited career growth due to its mature, LOE-approaching lifecycle and minimal linked job openings (0). Professionals should view this as a sunset brand role focused on margin preservation rather than expansion, with higher likelihood of team reduction or reassignment in the near term.